Self-Administered Parenteral Market Report 2026

The self-administered parenteral market size has grown steadily in recent years. It will grow from $25.84 billion in 2025 to $27.01 billion in 2026 at a compound annual growth rate (CAGR) of 4.5%. The growth in the historic period can be attributed to increasing chronic disease prevalence, adoption of home-based treatments, advances in prefilled syringes, rising awareness of self-injection therapy, biopharma growth.

The self-administered parenteral market size is expected to see steady growth in the next few years. It will grow to $32.19 billion in 2030 at a compound annual growth rate (CAGR) of 4.5%. The growth in the forecast period can be attributed to growth of smart injector technologies, integration with mobile health apps, personalized dosage solutions, expansion in autoimmune and oncology therapy, regulatory support for self-administration. Major trends in the forecast period include smart auto-injectors, prefilled syringe adoption, on-demand therapy delivery, telemedicine-linked devices, personalized drug dosage solutions.

The rising incidence of chronic diseases is expected to drive the growth of the self-administered parenteral market in the coming years. Chronic diseases are long-term medical conditions that generally develop slowly and often require ongoing management and treatment. Self-administered parenteral products allow patients to manage their treatment independently, which can significantly improve adherence compared to oral medications. For example, in June 2023, the Institute for Health Metrics and Evaluation, a US-based public health research institute, reported that over half a billion people worldwide were living with diabetes. This number is projected to more than double, reaching 1.3 billion by 2050. Therefore, the growing prevalence of chronic diseases is fueling the expansion of the self-administered parenteral market.

Key companies in the self-administered parenteral market are focusing on innovative solutions, such as the UDENYCA autoinjector, to provide patients with greater choice and control, making treatment more accessible. An autoinjector is a medical device designed to deliver a single dose of a drug, with administration triggered immediately and reliably by push-on-skin activation. For instance, in May 2023, Coherus BioSciences Inc., a US-based biotech company, launched the UDENYCA autoinjector in the US. This single-dose, prefilled autoinjector offers patients an additional administration option for pegfilgrastim. It is designed to be intuitive, delivering a full dose reliably through push-on-skin activation. The device also includes user-friendly features such as fast dosing, dual coverage, suitability for at-home and in-office use, and helps reduce the risk of febrile neutropenia.

In May 2024, Roche Holding AG, a Switzerland-based provider of pharmaceuticals and diagnostics, partnered with Enable Injections Inc. to combine Roche’s proprietary molecules with Enable’s enFuse wearable drug-delivery technology. This collaboration enables high-volume subcutaneous self-administration as an alternative to intravenous infusion. Enable Injections, a US-based company, specializes in wearable, on-body drug delivery systems capable of administering large-volume small-molecule and biologic therapeutics subcutaneously.

Major companies operating in the self-administered parenteral market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Roche Holding AG, Eli Lilly and Company, Novo Nordisk A S, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., Mylan N V, Terumo Corporation, Catalent Inc., West Pharmaceutical Services Inc., Gerresheimer AG, Biocon Limited, Insulet Corporation, Halozyme Therapeutics Inc., Ypsomed AG, Antares Pharma Inc., SHL Medical AG, Owen Mumford Ltd., Novartis AG, Kaleo Inc., Haselmeier AG, ScPharmaceuticals Inc., Fresenius Kabi AG.

North America was the largest region in the self-administered parenteral market in 2025. The regions covered in the self-administered parenteral market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the self-administered parenteral market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have significantly influenced the self-administered parenteral market by increasing costs for imported autoinjectors, pre-filled syringes, pen injectors, and advanced drug-delivery components. These cost increases are especially felt in Asia-Pacific and emerging economies where many injection devices and plastic or glass components are sourced from international suppliers. Higher device prices can slow adoption among patients who rely on home-based injections for chronic disease management. However, tariffs are driving investments in domestic manufacturing of injection devices and packaging materials, which is supporting innovation, reducing supply chain risk, and strengthening long-term growth prospects in the self-administered parenteral market.

The self-administered parenteral market research report is one of a series of new reports that provides self-administered parenteral market statistics, including self-administered parenteral industry global market size, regional shares, competitors with a self-administered parenteral market share, detailed self-administered parenteral market segments, market trends and opportunities, and any further data you may need to thrive in the self-administered parenteral industry. This self-administered parenteral market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Self-administered parenteral refers to the process of delivering medication or substances into the body through injections by the patient themselves. This approach offers greater autonomy and convenience, enabling patients to manage their conditions in a flexible and comfortable setting without frequent visits to healthcare facilities.

The primary product types in self-administered parenterals include pre-filled syringes, autoinjectors, pen injectors, and others. Pre-filled syringes are ready-to-use medical devices designed for the administration of liquid medications. They can be either disposable or reusable and are distributed through hospital pharmacies, online pharmacies, home healthcare providers, specialty clinics, and other channels. These products are used for conditions such as cardiovascular diseases, diabetes, osteoporosis, pain management, hormone replacement, and more.

The self-administered parenteral market consists of sales of biologic drugs, blood thinners, fertility drugs, osteoporosis medications, and insulin and inhaler devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.